Pharmacoperones as Novel Therapeutics for Diverse Protein Conformational Diseases
Open accessThe DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
After synthesis, proteins are folded into their native conformations aided by molecular chaperones. Dysfunction in folding caused by genetic mutations in numerous genes causes protein conformational diseases. Membrane proteins are more prone to misfolding due to their more intricate folding than soluble proteins. Misfolded proteins are detected by the cellular quality control systems, especially in the endoplasmic reticulum, and proteins may be retained there for eventual degradation by the ubiquitin-proteasome system or through autophagy. Some misfolded proteins aggregate, leading to pathologies in numerous neurological diseases. In vitro, modulating mutant protein folding by altering molecular chaperone expression can ameliorate some misfolding. Some small molecules known as chemical chaperones also correct mutant protein misfolding in vitro and in vivo. However, due to their lack of specificity, their potential as therapeutics is limited. Another class of compounds, known as pharmacological chaperones (pharmacoperones), binds with high specificity to misfolded proteins, either as enzyme substrates or receptor ligands, leading to decreased folding energy barriers and correction of the misfolding. Because many of the misfolded proteins are misrouted but do not have defects in function per se, pharmacoperones have promising potential in advancing to the clinic as therapeutics, since correcting routing may ameliorate the underlying mechanism of disease. This review will comprehensively summarize this exciting area of research, surveying the literature from in vitro studies in cell lines to transgenic animal models and clinical trials in several protein misfolding diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Identification of the Cystic Fibrosis Gene: Cloning and Characterization of Complementary DNA
Riordan, J. R., Rommens, J. M., Kerem, B.-S., Alon, N., Rozmahel, R., Grzelczak, Z., Zielenski, J., Lok, S., Plavsic, N., Chou, J.-L., et al. (1989) · Science · doi:10.1126/science.2475911 · Cited by 7,418
Principles that Govern the Folding of Protein Chains
Anfinsen, C. B. (1973) · Science · doi:10.1126/science.181.4096.223 · Cited by 7,096
A Receptor-Mediated Pathway for Cholesterol Homeostasis
Brown, M. S., & Goldstein, J. L. (1986) · Science · doi:10.1126/science.3513311 · Cited by 5,703
Pankiv, S., Clausen, T. H., Lamark, T., Brech, A., Bruun, J.-A., Outzen, H., Øvervatn, A., Bjørkøy, G., & Johansen, T. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m702824200 · Cited by 4,578
Identification of the Cystic Fibrosis Gene: Genetic Analysis
Kerem, B.-S., Rommens, J. M., Buchanan, J. A., Markiewicz, D., Cox, T. K., Chakravarti, A., Buchwald, M., & Tsui, L.-C. (1989) · Science · doi:10.1126/science.2570460 · Cited by 4,142
Endoplasmic Reticulum Stress Links Obesity, Insulin Action, and Type 2 Diabetes
Özcan, U., Cao, Q., Yilmaz, E., Lee, A.-H., Iwakoshi, N. N., Özdelen, E., Tuncman, G., Görgün, C., Glimcher, L. H., & Hotamisligil, G. S. (2004) · Science · doi:10.1126/science.1103160 · Cited by 3,844
Global analysis of protein expression in yeast
Ghaemmaghami, S., Huh, W.-K., Bower, K., Howson, R. W., Belle, A., Dephoure, N., O'Shea, E. K., & Weissman, J. S. (2003) · Nature · doi:10.1038/nature02046 · Cited by 3,750
Autophagy and the Integrated Stress Response
Kroemer, G., Mariño, G., & Levine, B. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.09.023 · Cited by 3,506
How many drug targets are there?
Overington, J. P., Al-Lazikani, B., & Hopkins, A. L. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2199 · Cited by 3,505
Protein aggregation and neurodegenerative disease
Ross, C. A., & Poirier, M. A. (2004) · Nature Medicine · doi:10.1038/nm1066 · Cited by 3,454 · cited 1×
“are directed to the following classical as well as current review articles on this topic for further information, with some of these articles focused on loss-of-function mutations and others focused on gain-of-function mutations (14, 15, 41, 56, 64, 65, 70, 129, 142, 212, 279, 312, 338, 344, 371, 392).”
BackgroundHarold, D., Abraham, R., Hollingworth, P., Sims, R., Gerrish, A., Hamshere, M. L., Pahwa, J. S., Moskvina, V., Dowzell, K., Williams, A., et al. (2009) · Nature Genetics · doi:10.1038/ng.440 · Cited by 3,326
Blinded by the Light: The Growing Complexity of p53
Vousden, K. H., & Prives, C. (2009) · Cell · doi:10.1016/j.cell.2009.04.037 · Cited by 3,163 · cited 1×
“p53 and associated cell-cycle pathways arrest the cell cycle and induce senescence and apoptosis in an emerging cancerous cell and upon cellular stress by controlling gene transcription as well as a variety of other mechanisms (381, 382).”
BackgroundProtein Misfolding, Amyloid Formation, and Human Disease: A Summary of Progress Over the Last Decade
Chiti, F., & Dobson, C. M. (2017) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-061516-045115 · Cited by 2,629 · cited 1×
“are directed to the following classical as well as current review articles on this topic for further information, with some of these articles focused on loss-of-function mutations and others focused on gain-of-function mutations (14, 15, 41, 56, 64, 65, 70, 129, 142, 212, 279, 312, 338, 344, 371, 392).”
BackgroundAdapting Proteostasis for Disease Intervention
Balch, W. E., Morimoto, R. I., Dillin, A., & Kelly, J. W. (2008) · Science · doi:10.1126/science.1141448 · Cited by 2,495 · cited 1×
“Proteostasis or protein homeostasis refers to the fact that at the cellular and subcellular (organelle) levels, it is essential to maintain homeostasis of proteins, with protein production, folding, and disposal reaching a balance (20, 216, 319).”
BackgroundThe Roles of PINK1, Parkin, and Mitochondrial Fidelity in Parkinson’s Disease
Pickrell, A. M., & Youle, R. J. (2015) · Neuron · doi:10.1016/j.neuron.2014.12.007 · Cited by 2,310
Aggresomes: A Cellular Response to Misfolded Proteins
Johnston, J. A., Ward, C. L., & Kopito, R. R. (1998) · The Journal of Cell Biology · doi:10.1083/jcb.143.7.1883 · Cited by 2,148 · cited 1×
“When the degradation is blocked by proteasome inhibitor, misfolded CFTR aggregates form aggresomes (114, 195, 390).”
BackgroundProtein degradation and protection against misfolded or damaged proteins.
Goldberg, A. L. (2003) · Nature · doi:10.1038/nature02263 · Cited by 2,088 · cited 11×
“To facilitate the maintenance of proteostasis, human cells employ ~1,400 proteins, including 332 molecular chaperones (comprising the chaperome) and their regulators, proteins involved in defending oxidative stress, and protein degradation machinery [ubiquitin-proteasome degradation system (UPS) and autophagy] (40, 14…”
BackgroundInfluentialMelanin pigmentation in mammalian skin and its hormonal regulation
Slominski, A., Tobin, D. J., Shibahara, S., & Wortsman, J. (2004) · Physiological Reviews · doi:10.1152/physrev.00044.2003 · Cited by 2,015 · cited 1×
“Tyrosinase catalyzes the oxidation of tyrosine and L-3,4-dihyroxyphenylalanine (DOPA) to dopaquinone (335).”
BackgroundUnfolding the role of protein misfolding in neurodegenerative diseases
Soto, C. (2003) · Nature Reviews Neuroscience · doi:10.1038/nrn1007 · Cited by 1,506 · cited 1×
“are directed to the following classical as well as current review articles on this topic for further information, with some of these articles focused on loss-of-function mutations and others focused on gain-of-function mutations (14, 15, 41, 56, 64, 65, 70, 129, 142, 212, 279, 312, 338, 344, 371, 392).”
BackgroundThe Biology of Proteostasis in Aging and Disease
Labbadia, J., & Morimoto, R. I. (2015) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-060614-033955 · Cited by 1,472 · cited 2×
“In young animals, these challenges are handled ably, but in aging animals, with decreased capacity to respond to these stresses, age-related diseases gradually manifest, especially if there is a genetic component, such as in familial amyotrophic lateral sclerosis (ALS), Parkinson’s disease, Huntington’s disease, Alzhe…”
BackgroundChaperone Suppression of α-Synuclein Toxicity in a Drosophila Model for Parkinson's Disease
Auluck, P. K., Chan, H. Y. E., Trojanowski, J. Q., Lee, V. M.-Y., & Bonini, N. M. (2002) · Science · doi:10.1126/science.1067389 · Cited by 1,227
Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809
Van Goor, F., Hadida, S., Grootenhuis, P. D. J., Burton, B., Stack, J. H., Straley, K. S., Decker, C. J., Miller, M., McCartney, J., Olson, E. R., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1105787108 · Cited by 1,088
Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound
Bykov, V. J. N., Issaeva, N., Shilov, A., Hultcrantz, M., Pugacheva, E., Chumakov, P., Bergman, J., Wiman, K. G., & Selivanova, G. (2002) · Nature Medicine · doi:10.1038/nm0302-282 · Cited by 1,067
A mitochondrial specific stress response in mammalian cells
Zhao, Q., Wang, J., Levichkin, I. V., Stasinopoulos, S., Ryan, M. T., & Hoogenraad, N. J. (2002) · The EMBO Journal · doi:10.1093/emboj/cdf445 · Cited by 1,026 · cited 1×
“It is a protective transcriptional response changing the expression of mitochondrial proteostasis genes (including chaperones and proteases) via mitochondrial-to-nuclear signaling (295, 327), that is, protein misfolding or misassembly in the mitochondrial matrix will result in upregulation of the expression of nuclear…”
BackgroundFunction and Regulation of Human Copper-Transporting ATPases
Lutsenko, S., Barnes, N. L., Bartee, M. Y., & Dmitriev, O. Y. (2007) · Physiological Reviews · doi:10.1152/physrev.00004.2006 · Cited by 864 · cited 1×
“Copper-transporting ATPase 1 that is localized in the trans-Golgi network functions as an intracellular pump to transport copper into the trans-Golgi network for incorporation into copper-requiring enzymes; those localized on the plasma membrane are involved in copper transport out of the cells (241).”
BackgroundHammond, C., Braakman, I., & Helenius, A. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.3.913 · Cited by 841 · cited 1×
“They bind to glycoproteins with monoglucosylated glycans (137, 147) so that these glycoproteins can be reglucosylated by the UDP-glucose:glycoprotein glucosyltransferase, an ER sensor for misfolded proteins (339).”
BackgroundMitonuclear communication in homeostasis and stress
Quirós, P. M., Mottis, A., & Auwerx, J. (2016) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2016.23 · Cited by 787 · cited 1×
“It is a protective transcriptional response changing the expression of mitochondrial proteostasis genes (including chaperones and proteases) via mitochondrial-to-nuclear signaling (295, 327), that is, protein misfolding or misassembly in the mitochondrial matrix will result in upregulation of the expression of nuclear…”
BackgroundHDAC6 and microtubules are required for autophagic degradation of aggregated huntingtin.
Iwata, A., Riley, B. E., Johnston, J. A., & Kopito, R. R. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m508786200 · Cited by 719 · cited 1×
“However, UPS is not effective against insoluble protein aggregates (171).”
BackgroundProtein misfolding in neurodegenerative diseases: Implications and strategies
Sweeney, P., Park, H., Baumann, M., Dunlop, J., Frydman, J., Kopito, R., McCampbell, A., Leblanc, G., Venkateswaran, A., Nurmi, A., et al. (2017) · Translational Neurodegeneration · doi:10.1186/s40035-017-0077-5 · Cited by 675 · cited 1×
“are directed to the following classical as well as current review articles on this topic for further information, with some of these articles focused on loss-of-function mutations and others focused on gain-of-function mutations (14, 15, 41, 56, 64, 65, 70, 129, 142, 212, 279, 312, 338, 344, 371, 392).”
BackgroundCollapse of proteostasis represents an early molecular event in Caenorhabditis elegans aging
Ben-Zvi, A., Miller, E. A., & Morimoto, R. I. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0902882106 · Cited by 649 · cited 2×
“In young animals, these challenges are handled ably, but in aging animals, with decreased capacity to respond to these stresses, age-related diseases gradually manifest, especially if there is a genetic component, such as in familial amyotrophic lateral sclerosis (ALS), Parkinson’s disease, Huntington’s disease, Alzhe…”
BackgroundPRIMA-1 reactivates mutant p53 by covalent binding to the core domain
Lambert, J. M. R., Gorzov, P., Veprintsev, D. B., Söderqvist, M., Segerbäck, D., Bergman, J., Fersht, A. R., Hainaut, P., Wiman, K. G., & Bykov, V. J. N. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.03.003 · Cited by 592
The Melanocortin-4 Receptor: Physiology, Pharmacology, and Pathophysiology
Tao, Y.-X. (2010) · Endocrine Reviews · doi:10.1210/er.2009-0037 · Cited by 531 · cited 2×
“For example, G98R MC4R can be efficiently escorted to the cell surface using pharmacoperones but cannot initiate signaling upon agonist stimulation (159, 350, 354).”
BackgroundSelf-citationJin, S. M., & Youle, R. J. (2013) · Autophagy · doi:10.4161/auto.26122 · Cited by 411
Peripheral Protein Quality Control Removes Unfolded CFTR from the Plasma Membrane
Okiyoneda, T., Barrière, H., Bagdány, M., Rabeh, W. M., Du, K., Höhfeld, J., Young, J. C., & Lukacs, G. L. (2010) · Science · doi:10.1126/science.1191542 · Cited by 408 · cited 2×
“Nonnative membrane proteins that escape the ER quality control monitoring or are generated in post-ER compartments are eliminated from the plasma membrane by this mechanism (9, 266).”
BackgroundLehmann, S., Bykov, V. J. N., Ali, D., Andrén, O., Cherif, H., Tidefelt, U., Uggla, B., Yachnin, J., Juliusson, G., Moshfegh, A., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.7783 · Cited by 406 · cited 1×
“One pharmacoperone, APR-246, shows promising results in a phase I/II clinical trial, being safe and effective in inducing cell cycle arrest, apoptosis, and target gene expression (224).”
BackgroundSome gating potentiators, including VX-770, diminish ΔF508-CFTR functional expression
Veit, G., Avramescu, R. G., Perdomo, D., Phuan, P.-W., Bagdany, M., Apaja, P. M., Borot, F., Szollosi, D., Wu, Y.-S., Finkbeiner, W. E., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008889 · Cited by 287
PRIMA-1MET synergizes with cisplatin to induce tumor cell apoptosis
Bykov, V. J. N., Zache, N., Stridh, H., Westman, J., Bergman, J., Selivanova, G., & Wiman, K. G. (2005) · Oncogene · doi:10.1038/sj.onc.1208419 · Cited by 252
Endoplasmic reticulum retention is a common defect associated with tyrosinase-negative albinism
Halaban, R., Svedine, S., Cheng, E., Smicun, Y., Aron, R., & Hebert, D. N. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.11.5889 · Cited by 179 · cited 1×
“The mutant tyrosinases are retained in the ER and have prolonged association with calnexin and calreticulin (32, 135).”
BackgroundBenjamin, E. R., Flanagan, J. J., Schilling, A., Chang, H. H., Agarwal, L., Katz, E., Wu, X., Pine, C., Wustman, B., Desnick, R. J., et al. (2009) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-009-1077-0 · Cited by 173
Macrophage models of Gaucher disease for evaluating disease pathogenesis and candidate drugs
Aflaki, E., Stubblefield, B. K., Maniwang, E., Lopez, G., Moaven, N., Goldin, E., Marugan, J., Patnaik, S., Dutra, A., Southall, N., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008659 · Cited by 126
Folding Efficiency Is Rate-limiting in Dopamine D4 Receptor Biogenesis
Van Craenenbroeck, K., Clark, S. D., Cox, M. J., Oak, J. N., Liu, F., & Van Tol, H. H. M. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m414043200 · Cited by 107
Cited by
Protein quality control in the secretory pathway
Sun, Z., & Brodsky, J. L. (2019) · Journal of Cell Biology · doi:10.1083/jcb.201906047 · Cited by 387
The melanocortin pathway and control of appetite-progress and therapeutic implications
Baldini, G., & Phelan, K. D. (2019) · Journal of Endocrinology · doi:10.1530/joe-18-0596 · Cited by 272
Second-Generation Pharmacological Chaperones: Beyond Inhibitors
Tran, M. L., Génisson, Y., Ballereau, S., & Dehoux, C. (2020) · Molecules · doi:10.3390/molecules25143145 · Cited by 63
Liu, T., Ji, R.-L., & Tao, Y.-X. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.108044 · Cited by 34
Self-citationFerrero, E., Di Gregorio, E., Ferrero, M., Ortolan, E., Moon, Y.-A., Di Campli, A., Pavinato, L., Mancini, C., Tripathy, D., Manes, M., et al. (2023) · Human Genetics · doi:10.1007/s00439-023-02572-y · Cited by 9
Metadata
- Authors
- Tao, Y.-X., & Conn, P. M.
- Venue
- Physiological Reviews
- Publisher
- American Physiological Society
- Published
- 2018-04-01
- Volume
- 98
- Issue
- 2
- Pages
- 697-725
- ISSN
- 0031-9333 (ISSN-L)
- 1522-1210
- OpenAlex
- W2785523533
- Cited by
- 115
- References
- 41
- FWCI
- 1.25
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.